LL37-TP5 Hybrid Peptide: Rational Design for Dual LPS Neutralization and TLR4-Mediated Anti-Inflammatory Activity

The LL37-TP5 hybrid peptide exemplifies a structurally deliberate chimeric strategy in which the cationic, amphipathic α-helical scaffold of human cathelicidin LL-37 (residues 13–37 of the mature hCAP18 cleavage product) is conjugated to TP5 (Thymopentin, Arg-Lys-Asp-Val-Tyr), a thymic immunomodulatory pentapeptide, to produce a bifunctional agent capable of neutralizing lipopolysaccharide (LPS) at the lipid A moiety while concurrently suppressing downstream TLR4/MD-2 complex signaling, NF-κB nuclear translocation, and MAPK (p38 and ERK1/2) phosphorylation in macrophage and dendritic cell lineages. Early 2026 structural pharmacology data from murine RAW 264.7 macrophage models and human THP-1 monocyte-derived macrophages position this hybrid as one of the most mechanistically sophisticated anti-endotoxin peptide constructs currently under preclinical evaluation.

Structural Pharmacology of the LL-37 Scaffold: Why the Cathelicidin Core Matters

Native LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES, 37 aa) adopts a disrupted amphipathic helix between residues 2–31 in aqueous environments, with a cationic face (net charge +6 at physiological pH) that confers high-affinity electrostatic binding to the anionic phosphate groups of lipid A — the bioactive core of gram-negative bacterial LPS. Surface plasmon resonance (SPR) studies have established a KD of approximately 0.3–1.2 µM for LL-37:LPS interactions, with binding kinetics dominated by rapid association (kon ~10⁵ M⁻¹s⁻¹) and slow dissociation. Critically, this neutralization is not merely sequestration: LL-37 physically disrupts LPS aggregate structure (as confirmed by dynamic light scattering and TEM data), reducing its ability to form the MD-2-activating LPS:LBP:CD14 ternary complex that presents lipid A to TLR4.

Beyond direct LPS neutralization, LL-37 also modulates TLR4 signaling at the receptor level. Fluorescence resonance energy transfer (FRET) studies in HEK293T cells overexpressing TLR4/MD-2 demonstrate that LL-37 reduces TLR4 dimerization efficiency by approximately 40% at 5 µM — a finding that implicates allosteric receptor-level interference independent of LPS binding. This dual mechanism (LPS capture + receptor modulation) is architecturally preserved and amplified in the LL37-TP5 chimeric construct.

TP5 (Thymopentin): Immunomodulatory Mechanism and Rationale for Hybridization

TP5 (Arg-Lys-Asp-Val-Tyr) is the active pentapeptide sequence corresponding to residues 32–36 of thymopoietin II. Its primary immunoregulatory mechanism operates via CD80/CD86 co-stimulatory molecule downregulation on antigen-presenting cells, suppression of IL-12p70 and TNF-α secretion in LPS-challenged dendritic cells, and promotion of regulatory T cell (Treg) differentiation through FOXP3 upregulation in CD4⁺CD25⁺ T cell subsets. At concentrations of 10–100 nM, TP5 reduces IL-6 and IL-1β release in LPS-stimulated human PBMC cultures by 35–55% in a dose-dependent fashion, with EC50 values in the range of 20–40 nM for cytokine suppression.

The rationale for fusing TP5 to LL-37 is mechanistically elegant: while LL-37 operates primarily at the extracellular LPS:TLR4 interface and at the membrane level, TP5 targets intracellular and lymphocytic immunomodulation. The hybrid therefore recruits complementary, non-overlapping anti-inflammatory arms — a critical design criterion for combating the complex, multi-stage inflammatory cascades characteristic of sepsis-associated endotoxemia, gram-negative pneumonia, and peritonitis models.

LL37-TP5 Chimeric Architecture: Linker Design and Conformational Considerations

The majority of published LL37-TP5 hybrid constructs employ a flexible Gly-Gly-Gly-Ser (G₃S) or Gly₄Ser linker between the C-terminus of a truncated LL-37 fragment (typically residues 17–32 or the KR12 core sequence, KRIVQRIKDFLR) and the N-terminus of the TP5 pentapeptide. This linker architecture preserves the independent folding of each functional domain while minimizing steric clash, as confirmed by circular dichroism (CD) spectroscopy showing the LL-37 fragment retains >85% α-helical content in 50% TFE and >60% in LPS-containing aqueous buffer — a prerequisite for membrane-disruptive and LPS-binding activity.